SENTARA HEALTH PLANS

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid)</u> on this request. All other information may be filled in by office staff; <u>fax to 1-800-750-9692</u>. No additional phone calls will be necessary if all information (<u>including phone and fax #s</u>) on this form is correct. <u>If the information provided is not complete, correct, or legible, the authorization process can be delayed.</u>

NON-PREFERRED

☐ HP Acthar® Gel (repository corticotronin)

Drug Requested: Repository Corticotropin Medications - INFANTILE SPASMS (IS)

PREFERRED

☐ Purified Cortrophin[™] Gel

provided or request may be denied.

- Turnica cortropinii Ger	= III Tiethai Ger (repository corticouropin)					
(repository corticotropin)	*Member must have tried and failed preferred Purified Cortrophin™ Gel and meet all applicable PA criteria below					
Acthar Gel single-dose pre-filled SelfJect inje	ector is for subcutaneous administration by adults only.					
MEMBER & PRESCRIBER INFORM	ATION: Authorization may be delayed if incomplete.					
Member Name:						
Member Sentara #:	Date of Birth:					
Prescriber Name:						
Prescriber Signature:						
Office Contact Name:						
	er: Fax Number:					
NPI #:						
DRUG INFORMATION: Authorization m	nay be delayed if incomplete.					
Drug Name/Form/Strength:						
Dosing Schedule:	Length of Therapy:					
Diagnosis:	ICD Code, if applicable:					
Weight (if applicable):	Date weight obtained:					
	tudy showed similar efficacy between low-dose (20-30 IU) v dose ACTH should be considered as an alternative to high Level B).					

(Continued on next page)

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be

- ☐ Prescriber MUST be a Neurologist
- ☐ Member MUST have a documented diagnosis of Infantile Spasms
- Approval will only be granted for a <u>MAXIMUM</u> of <u>30 days only</u> due to similar adverse effects of corticosteroids. After 2 weeks of treatment, dosing should be gradually tapered and discontinued over a 2-week period. The following is one **suggested** tapering schedule:
 - 30 U/m² in the morning for 3 days; 15 U/m² in the morning for 3 days; 10 U/m² in the morning for 3 days; and 10 U/m² every other morning for 6 days.
- □ Complete the regimen below (repository corticotropin is supplied as 5 mL multi-dose vial containing 80 USP Units per mL):

Approval will be a MAXIMUM of 30 days only (combined inpatient and outpatient time period)

Initial Hose Schedille				at Outpatient pharmacy will be based ne needed at discharge from hospital			
75 U/m ² BID x	days	TOTAL	mL	X	# days (max	29 days)	
Taper Dose Schedule			BODY SURFACE AREA BSA				
30 U/m ² QD x	days	mL x	days	Weight:		kg	
15 U/m ² QD x	days	mL x	days	Height/I	Length:		in.
10 U/m ² QD x	days	mL x	days	Calculat	ed BSA:		m^2
10 U/m ² QOD x	days	mL x	days				

TOTAL Number of vials needed:	/days	(max 29 d	lays

Medication being provided by Specialty Pharmacy - Proprium Rx

Not all drugs may be covered under every Plan

If a drug is non-formulary on a Plan, documentation of medical necessity will be required.

**Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. **

*Previous therapies will be verified through pharmacy paid claims or submitted chart notes. *

^{*}Approved by Pharmacy and Therapeutics Committee: 2/21/2008; 9/26/2024 UPDATED/REVISED/REFORMATTED: 1/9/2020; 6/16/2022;10/26/2023;10/15/2024